COSCIENS Biopharma Profit Margin

COSCIENS Biopharma (CSCI) currently reports a profit margin of -57.58% as of June 2026. That compares with -201.85% in the prior-year period — up 71.5% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore COSCIENS Biopharma's profit margin history and peer comparisons.

COSCIENS Biopharma's profit margin increased from -201.85% to -57.58% — a 71.5% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

COSCIENS Biopharma's profit margin of -57.58% is lower than the Healthcare sector average of 21.34%. That is roughly 369.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but COSCIENS Biopharma's current -57.58% should be judged against Healthcare norms (sector average: 21.34%) and against CSCI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -57.58%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for COSCIENS Biopharma, and consider following CSCI for alerts when major investors trade the stock.